肝细胞癌与其他晚期实体瘤患者免疫治疗相关肝损伤的特征与结局比较
本研究比较肝细胞癌(HCC)与其他实体瘤患者接受免疫检查点抑制剂(ICI)后免疫相关肝损伤(irLI)的发生率、特征与结局。HCC队列来自AB-real研究(375例,一线阿替利珠单抗+贝伐珠单抗),非HCC队列来自INVIDIa-2研究(459例,一线ICI)。HCC患者irLI发生率更高、发生更早,但缓解率更高、激素需求更低,肝功能失代偿和治疗中断风险低,未 negatively 影响肿瘤结局。
要点
- HCC患者任何级别irLI发生率为11.4%,非HCC患者为2.6%。
- 暴露调整后irLI发生率HCC为22.1/100患者年,非HCC为2.1/100患者年(p<0.001)。
- HCC患者irLI发生更早(中位1.4个月 vs 4.7个月),但激素使用更少、缓解率更高。
核心结论
- HCC患者irLI发生率更高、发生更早,但缓解率更高、皮质类固醇需求更低,肝功能失代偿和治疗中断风险低,未 negatively 影响肿瘤结局。
研究设计与样本
- 两项前瞻性队列:HCC队列为AB-real研究中375例不可切除/晚期HCC、Child-Pugh A级、一线阿替利珠单抗+贝伐珠单抗治疗患者;非HCC队列为INVIDIa-2多中心研究中459例一线ICI治疗患者。
- irLI定义为排除其他肝损伤病因后治疗相关的转氨酶升高,发生率按治疗暴露时间调整。
主要发现
- HCC患者任何级别irLI发生率为11.4%(中位暴露4.4个月,95%CI 3.7-5.2),非HCC患者为2.6%(中位暴露12.4个月,95%CI 11.1-14.0)。
- 暴露调整后irLI发生率HCC为22.1/100患者年,非HCC为2.1/100患者年(p<0.001),中位至irLI时间分别为1.4个月和4.7个月。
- 发生irLI的患者中,HCC组16.3%使用全身皮质类固醇,非HCC组75.0%(p<0.001);irLI缓解率分别为72.1%和58.3%(p=0.362)。
- HCC患者因irLI导致肝功能失代偿和治疗中断率均为7%。
- HCC患者中1-2级irLI与总生存改善相关(HR 0.53,95%CI 0.29-0.96)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune-related liver injury (irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors (ICIs). We aimed to compare the incidence, clinical characteristics, and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma (HCC) vs. other solid tumours. METHODS: Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line atezolizumab+bevacizumab from the AB-real study, and a non-HCC cohort including 459 patients treated with first-line ICI therapy from the INVIDIa-2 multicentre study. IrLI was defined as a treatment-related increase of aminotransferase levels after exclusion of alternative aetiologies of liver injury. The incidence of irLI was adjusted for the duration of treatment exposure. RESULTS: In patients with HCC, the incidence of any grade irLI was 11.4% over a median treatment exposure of 4.4 months (95% CI 3.7-5.2) vs. 2.6% in the INVIDIa-2 cohort over a median treatment exposure of 12.4 months (95% CI 11.1-14.0). Exposure-adjusted-incidence of any grade irLI was 22.1 per 100-patient-years in patients with HCC and 2.1 per 100-patient-years in patients with other solid tumours (p <0.001), with median time-to-irLI of 1.4 and 4.7 months, respectively. Among patients who developed irLI, systemic corticosteroids were administered in 16.3% of patients with HCC and 75.0% of those without HCC (p <0.001), and irLI resolution was observed in 72.1% and 58.3%, respectively (p = 0.362). In patients with HCC, rates of hepatic decompensation and treatment discontinuation due to irLI were 7%. Grade 1-2 irLI was associated with improved overall survival only in patients with HCC (hazard ratio 0.53, 95% CI 0.29-0.96). CONCLUSIONS: Despite higher incidence and earlier onset, irLI in patients with HCC is characterised by higher rates of remission and lower requirement for corticosteroid therapy (vs. irLI in other solid tumours), low risk of hepatic decompensation and treatment discontinuation, not negatively affecting oncological outcomes. IMPACT AND IMPLICATIONS: Immune-related liver injury (irLI) is common in patients with cancer receiving immune checkpoint inhibitors (ICIs), but whether irLI is more frequent or it is associated with a worse clinical course in patients with hepatocellular carcinoma (HCC), compared to other tumours, is not known. Herein, we compared characteristics and outcomes of irLI in two prospective cohorts including patients treated with ICIs for HCC or for other oncological indications. irLI is significantly more common and it occurs earlier in patients with HCC, also after adjustment for duration of treatment exposure. However, outcomes of patients with HCC who developed irLI are not negatively affected in terms of requirement for corticosteroid therapy, hepatic decompensation, treatment discontinuation and overall survival.
引用
- Celsa C, Cabibbo G, Fulgenzi CAM, et al. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. J Hepatol. 2023. PMID: 37972660. doi:10.1016/j.jhep.2023.10.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。